 The trial uses an optimal 2 stage design targeting for a true response proportion greater than 30. Nine patients will be treated initially with expansion to 29 patients if a response is seen in one of the initial nine patients treated. If no response is seen at the 9 mcgkgd dose an additional 9 patients will be treated at a dose of 18 mcgkgd with expansion to 29 patients at this dose level if a response is seen. A stopping rule for excessive toxicity will be incorporated. 